Protagonist Therapeutics, Inc. (PTGX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Protagonist Therapeutics, Inc. (PTGX) closed at USD 136.28 on 2026-10-14, a change of +73.6 % over the past year, with a market capitalization of USD 8.84B.

Protagonist Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Protagonist Therapeutics, Inc. key figures

Previous close

USD 136.28 (2026-10-14)

1-year change

+73.6 %

Market cap

USD 8.84B

Enterprise value

USD 8.06B

P/E ratio (trailing)

135.20

P/E ratio (forward)

-891.84

EPS (trailing)

1.01

EPS (forward)

-0.15

PEG ratio

n/a

Price to book

10.49

Revenue growth

3,749.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

13.63

Employees

141

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Protagonist Therapeutics, Inc. and compare it with other stocks.